How to Reduce Unnecessary Compliance Costs - By identifying and eliminating non-value-added activities, drug manufacturers can avoid falling into the same cost-traps in the future. - BioPharm

ADVERTISEMENT

How to Reduce Unnecessary Compliance Costs
By identifying and eliminating non-value-added activities, drug manufacturers can avoid falling into the same cost-traps in the future.


BioPharm International
Volume 23, Issue 7


James P. Catania
For biopharmaceutical companies, the total cost of current good manufacturing practice (cGMP) compliance has become a significant percentage of the cost of goods sold. Some of the cost is driven by increasing regulation. What drives much of the cost, however, is the evolution of activities that might be unnecessary. Successful organizations adopt an approach to compliance that focuses not only on the costs of quality assurance (QA), quality control (QC), and regulatory affairs activities, but also on the underlying and often hidden factors that drive excessive cost throughout all functional groups in the organization. They do so by applying some basic activity-costing principles to compliance functions that provide these savvy organizations with opportunities to simultaneously reduce cost and improve compliance effectiveness.

A MORE REVEALING WAY TO ANALYZE COMPLIANCE ACTIVITIES

Figure 1 shows the three basic activity–cost buckets into which an organization's activities can be separated.

When a percentage value-added analysis is conducted, compliance-related activities, particularly those associated with QA and QC, typically are categorized as business value added (BVA) activities. BVA activities are not directly involved in the conversion process (converting raw materials into product) but are essential because without them, the product can not be produced and sold.

This method of accounting for compliance can be useful but it conceals as much as it reveals. The activities and resources (costs) used to do what is actually necessary to meet regulatory requirements generally are only a fraction of the total spent by an organization. The problem begins with automatically categorizing all activities and costs associated with compliance-related functional groups as BVA. Many of the activities and associated costs are, in fact, non-value–added (NVA). These are NVA because they have nothing to do with the conversion process and they actually contribute nothing to achieving compliance.

Differentiating between BVA and NVA in compliance is challenging because it requires stepping back and looking at the function in a different way. Instead of automatically seeing compliance activities as BVA, we have to look more closely; and when we do, we find that many of those activities are in fact NVA.

NVA compliance activities arise in two ways:

  • they are driven directly by failure
  • they are driven by anticipation of failure.

The first step toward more cost-effective and improved compliance is to understand those two forms of NVA activities.


blog comments powered by Disqus

ADVERTISEMENT

Moscow Hosts IFPMA Biosimilars Conference
May 17, 2013
AbbVie and Alvine Will Collaborate on Celiac Disease Therapy
May 15, 2013
FDA Issues Pharmacoepidemiologic Safety Study Guidance
May 14, 2013
USP Launches Initiative to Fight Counterfeit Drugs in Sub-Saharan Africa
May 13, 2013
Amgen Forms New Joint Venture to Commercialize Vectibix in China
May 13, 2013
Upcoming Conferences
UPCOMING CONFERENCES

Access Programs for Investigational and Pre-Launch Drugs
Philadelphia, PA | July 17-18, 2013
Request Brochure

Strategic Pipeline Planning & Portfolio Valuation
Philadelphia, PA | August 13-14, 2013
Request Brochure

MES 2013 - Forum on Manufacturing Execution Systems
Philadelphia, PA | August 14-15, 2013
Request Brochure

Mobile Innovation for the Life Sciences Industry
Philadelphia, PA | August 20-21, 2013
Request Brochure

See All Conferences >>

ADVERTISEMENT

Author Guidelines
FindPharma
Source: BioPharm International,
Click here